A phase I/II clinical trial of a Chimeric antigen receptor-T cell therapy
Latest Information Update: 08 Feb 2022
At a glance
- Drugs Chimeric antigen receptor T cell therapy Alaya.bio (Primary)
- Indications Cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 14 Jul 2020 New trial record
- 22 Jun 2020 According to a Rexgenero media release, this trial is planned for 2020.